Avricore Health granted Options exercisable for 3,300,000 common shares at CAD $0.06 per share. The awards vest quarterly and expire five years after grant, subject to recipients remaining directors, officers, employees or consultants, while HealthTab’s Abbott collaboration supports distribution of point-of-care testing products through UK pharmacies.

Key Highlights

  • The options expire five years after their grant date, subject to continued service.
  • HealthTab can distribute Abbott’s Afinion TM 2 Analyzer through NHS-linked pharmacies in the UK.
  • The Abbott collaboration creates a framework for expanding point-of-care testing through community pharmacies.

Avricore Health Inc. (OTC: AVCRF) approved options exercisable for 3,300,000 common shares at an exercise price of CAD $0.06 per share. The awards cover directors, officers, employees and consultants, with quarterly vesting beginning on the grant date.

Option Terms Tie Awards to Continued Service

Vesting starts quarterly from the grant date. Each option expires five years after its grant date. The awards remain conditional on recipients continuing to serve as directors, officers, employees or consultants of Avricore Health. The company’s board approved the grants.

HealthTab Adds Abbott Testing Products in the UK

HealthTab Ltd, Avricore Health’s wholly owned subsidiary, announced on August 20, 2026, that it had entered into a formal collaboration with Abbott. HealthTab can distribute Abbott’s Afinion TM 2 Analyzer through NHS-linked pharmacies for HbA1c and lipid-profile testing. The arrangement also establishes a framework for expanding point-of-care testing through community pharmacies. HealthTab’s platform includes instruments, consumables, onboarding, Training and ongoing support, alongside a cloud-based system connecting analyzers, patient results, quality-control data and pharmacist workflows.